Dual-agonist survodutide reduces liver fat and weight in phase 3 MASLD trial
In the SYNCHRONIZE-MASLD phase 3 trial, 216 adults with obesity and metabolic dysfunction-associated steatotic liver disease received weekly survodutide 6.0 mg or placebo for 48 weeks. Survodutide met both co-primary endpoints, with 84.2% achieving ≥30% reduction in liver fat content (MRI-PDFF) versus 24.3% on placebo, and significant weight loss compared with placebo. About six in ten treated participants reached normalization of liver fat. The study used a dose-escalation period to 6.0 mg followed by a maintenance phase and included extensive safety monitoring. Secondary endpoints showed favorable changes in liver enzymes, liver stiffness/volume, insulin resistance, and other noninvasive liver tests. These results support survodutide as a potential therapy for obesity and MASLD, with data sharing and ongoing follow-up planned.